Citation: Lung Cancer. 2020, 139
Author: Lester J.; Powell C.; Khan S.; Escriu C.; Hudson E.; Conn A.; Mansy T.; Chan S.; Brock J.; Zhuo X.; Zhang X.; Pawar V.; Durand A.
Abstract: Introduction: There are limited data regarding the current treatment patterns for aNSCLC in the United Kingdom. This study aims to overcome this gap by evaluating data from 8 UK hospitals (representing approximately 10% of all UK patients with aNSCLC). To our knowledge, this is the first large-scale UK-based real-world study in this patient population. Method(s): This retrospective study used electronic prescribing records (EPRs) and chart review of treatment-naive patients with aNSCLC starting first-line (1L) treatment between June 2016 and March 2018 (follow-up until December 2018). Line of treatment was defined by the treating physician within the EPRs. Data presented are from interim analyses (IA) and are descriptive. Result(s): A total of 1113 patients initiated 1L treatment: 814 (73.1%) received chemotherapy, 186 (16.7%) received immunotherapy (IO; all monotherapy), and 113 (10.2%) received targeted therapy (TT; ALK and EGFR inhibitors). Median age at diagnosis was 68.0 years (range, 29-93; among 613 patients with age information available at IA), and 54.1% were male. 1L IO therapy usage increased from 3% in June 2016 to 21% in March 2018, while chemotherapy usage decreased from 78% to 70%. Among the patients who advanced to 2L (n=385), 188 (48.8%) received chemotherapy, 123 (31.9%) received IO therapy, and 74 (19.2%) received TT. For the subgroup who initiated 1L chemotherapy or IO therapy, chemotherapy was the most commonly used 2L treatment, whereas most patients receiving TT in 1L (89.2%) continued TT in 2L (Table 1). Conclusion(s): As a percentage of total 1L treatment, IO therapy usage has increased in recent years. However, the majority of the patients with aNSCLC were treated with 1L chemotherapy regimens. Among patients who received 2L treatment, most received chemotherapy or IO therapy. Future analyses should focus on evaluating clinical outcomes in patients with aNSCLC by choice of 1L treatment and treatment sequencing. Disclosure: J. Lester: honoraria, sponsorship, advisory board participation from Roche, AstraZeneca, Pfizer, Boehringer-Ingelheim, MSD, BMS, and Lilly; S. Khan and J. Brock: no relevant conflict of interest to declare; C. Powell: received sponsorship to conferences from Boehringer-Ingelheim and Roche and honoraria for talks/session chairing from Boehringer-Ingelheim and Bristol-Myers-Squibb (but not within the last 12 months); C. Escriu: travel grants from MSD, Roche, AstraZeneca and Boehringer-Ingelheim, consultancy fees from MSD, AstraZeneca and Boehringer-Ingelheim, lecturer fees from Pfizer, AstraZeneca and Roche; E. Hudson: Advisory Board work for Roche and Tesaro; A. Conn: educational grants from Lilly, AstraZeneca, Boehringer-Ingelheim; T. Mansy: honorarium and congress travel funding from: MSD, Bristol-Myers-Squibb, PharmaMar, AstraZeneca, Roche, Tesaro, Amgen; S. Chan: honoraria for presentation from Bristol-Myers-Squibb; X. Zhuo: employee of Merck KgaA employee when the analysis was conducted; A. Durand: employee of Merck Serono Limited; X. Zhang and V. Pawar: employee of EMD Serono Inc. Table Presented Copyright © 2020 Elsevier B.V.
